Skip to content

Clinical Study to Evaluate the Performance and Safety of AI-OR-001

Clinical Study to Evaluate the Performance and Safety of AI-OR-001

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs022210064
Enrollment
2
Registered
2022-01-14
Start date
2022-03-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart Disease

Interventions

Using an unapproved medical device

Sponsors

Nasu Kenya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Target lesion: Coronary Chronic Total Occlusion (CTO) with a target vessel diameter of 1.0 to 4.0 mm, to which a retrograde approach is applicable 2.Ages: 20 years and older 3.Sexes: All 4.Willing and able to provide written informed consent

Exclusion criteria

Exclusion criteria: 1.Retrograde approach is not applicable for CTO-PCI 2.Undergo PCI for Acute Coronary Syndrome 3.Inability to take antiplatelet medications 4.Pregnant, have childbearing potential, within 28 days after childbirth or lactating 5.With a history of serious allergic reactions to contrast materials or other drugs required for the procedure 6.With a history of coronary artery spasm 7.Coronary artery bypass grafting is not applicable 8.May have difficulty in participating in this study due to psychiatric disorder

Design outcomes

Primary

MeasureTime frame
Device Success (guiding the antegrade and retrograde guidewires into the same space and guiding the retrograde guidewire into the antegrade guiding catheter)

Contacts

Public ContactKenya Nasu

Toyohashi Heart Center

nasu@heart-center.or.jp+81-532-37-3377

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026